Hot Products
Hot products from BioCrick which is a professional high-purity natural products manufacturer are well known to scientists around the world because of their high purity and stability. Each product is a chemical compound or substance produced by a living organism—that is, found in nature. In the broadest sense, natural products include any substance produced by life.Natural products remain the best sources of drugs and drug leads, and this remains true today despite the fact that many pharmaceutical companies have deemphasized natural products research in favor of HTP screening of combinatorial libraries during the past 2 decades. From 1940s to date, 131 (74.8%) out of 175 small molecule anticancer drugs are natural product-based/inspired, with 85 (48.6%) being either natural products or derived therefrom. From 1981 to date, 79 (80%) out of 99 small molecule anticancer drugs are natural product-based/inspired, with 53 (53%) being either natural products or derived therefrom. Among the 20 approved small molecule New Chemical Entities (NCEs) in 2010, a half of them are natural products.
Hot products from the professional high-purity natural products manufacturer
| Cat.No. | Product Name |
|---|---|
| BCC6358 | ICA 121431 |
| Potent and selective inhibitor of human NaV1.3 and NaV1.1 channels (IC50 values are 13 and 23 nM respectively). Exhibits up to 1,000 fold selectivity against other TTX-sensitive or resistant sodium channels (IC50 values are >10 μM for human NaV1.5 and NaV1.8 channels). Interacts with an inhibitory interaction site distinct from those bound by TTX and local anesthetic-like modulators. | |
| BCC6360 | J 147 |
| Potent neuroprotective and neurotrophic compound. Protects against neurotoxicity in cortical neurons in vitro (EC50 = 25 - 200 nM). Reduces soluble Aβ40 and Aβ42 levels and increases BDNF levels in the hippocampus in vivo. Enhances memory in wild type rats. Prevents memory deficits and rescues cognitive deficits in young and aged transgenic Alzheimer's disease mice, respectively. Orally active. | |
| BCC6408 | SBE 13 HCl |
| Selective inhibitor of PLK1 (IC50 values are 200 pM, 875 nM and 66 μM for PLK1, PLK3 and PLK2 respectively). Exhibits no effect on Aurora kinase A activity. Binds and stabilizes the inactive form of PLK1. Delays cell cycle progression, reduces cell proliferation and induces apoptosis in a range of human cancer cell lines. Transiently arrests cells cycle at G0/G1 in primary cells. | |
| BCC6420 | Spautin-1 |
| Inhibitor of autophagy; inhibits USP10 and USP13 activity (IC50 values are 0.6 and 0.7 μM respectively) and promotes degradation of Vps34 (class III PI 3-kinase) complexes. Selectively promotes apoptosis of cancer cells under starvation conditions. Prevents the PDGF-induced conversion from the contractile to synthetic phenotype in vascular smooth muscle cells. | |
| BCC6431 | Rostafuroxin (PST 2238) |
| Na+/K+ ATPase modulator. Normalizes renal Na+/K+ ATPase pump function in mutant adducin- and endogenous ouabain-dependent forms of hypertension. Reduces blood pressure in Milan hypersensitive rats. Controls mania-like behaviors in Myshkin mice having a Na+/K+ ATPase α3 subunit mutation. | |
| BCC6432 | CARIPORIDE |
| Selective Na+/H+ exchanger isoform 1 (NHE1) inhibitor (IC50 values are 0.05, 3 and 1000 μM for NHE1, NHE3 and NHE2 respectively). Attenuates ischemia-induced cardiomyocyte apoptosis in vitro. Reduces cardiac arrhythmia in vivo. Also promotes apoptosis in cancer cells overexpressing NHE1. Orally active. | |
| BCC6439 | Tiplaxtinin(PAI-039) |
| Plasminogen activator inhibitor-1 (PAI-1) inhibitor (IC50 = 2.7 μM). Induces vascular smooth muscle cell apoptosis in vitro and reduces carotid artery neointimal formation in a rat vascular injury model. Promotes thrombolysis in rat and dog models of acute arterial thrombosis. Orally available. | |
| BCC6478 | UF 010 |
| Class I HDAC inhibitor (IC50 values are 0.06, 0.1, 0.5 and 1.5 μM for HDACs 3, 2, 1 and 8, respectively). Exhibits >6-fold selectivity over other HDACs. Induces accumulation of acetylated histones in HCT116 cells in vitro. Inhibits proliferation of a range of cancer cell lines. Arrests cells at G1/S transition. | |
